Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

LESSONS LEARNED. A phase I study of the pan‐class I phosphoinositide 3‐kinase inhibitor pilaralisib (in capsule formulation) in advanced solid tumors established the maximum tolerated dose as 600 mg once daily. The current study investigated pilaralisib in tablet formulation. Pilaralisib tablets wer...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncologist
Main Authors: Edelman, Gerald, Rodon, Jordi, Lager, Joanne, Castell, Christelle, Jiang, Jason, Van Allen, Eliezer M., Wagle, Nikhil, Lindeman, Neal I., Sholl, Lynette M., Shapiro, Geoffrey I.
Format: Artigo
Sprog:Inglês
Udgivet: AlphaMed Press 2018
Fag:
Clinical Trial Results
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5896717/
https://ncbi.nlm.nih.gov/pubmed/29593099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0691
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker